Amarin knows pretty well if the interim date has occurred or when it will occur. The FDA obviously is content to negotiate until R-IT is unblinded. The fact that Amarin agrees to this is IMO a sign that Amarin feels that the resolution of R-IT with a stop for efficacy is near. Otherwise why not opt for a PI, raise some cash, and wait for 2018.